Intrinsic Value of S&P & Nasdaq Contact Us

Cronos Group Inc. CRON NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
50/100
2/7 Pass
SharesGrow Intrinsic Value
$7.81
+203.9%
Analyst Price Target
$2.30
-10.5%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cronos Group Inc. (CRON) has a negative trailing P/E of -102.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 34.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.98%, forward earnings yield 2.92%. PEG 1.32.

Criteria proven by this page:

  • VALUE (49/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
  • Forward P/E 34.3 — analysts expect a return to profitability with estimated EPS of $0.08 for FY2026.
  • PEG Ratio 1.32 — between 1.0–2.0 indicates moderate valuation relative to growth.
  • Trailing Earnings Yield -0.98% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.92% as earnings recover.
  • Analyst consensus target $2.30 (-10.5% downside) — slight downside risk — the market may be ahead of analyst expectations.

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
50/100
SG Score
View full scorecard →
~
VALUE
49/100
Price-to-Earnings & upside
Proven by this page
FUTURE
16/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
50/100
→ Income
GROWTH
100/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — CRON

Valuation Multiples
P/E (TTM)-102.1
Forward P/E34.3
PEG Ratio1.32
Forward PEG1.32
P/B Ratio0.88
P/S Ratio6.51
EV/EBITDA5.3
Per Share Data
EPS (TTM)$-0.02
Forward EPS (Est.)$0.08
Book Value / Share$2.98
Revenue / Share$0.39
FCF / Share$0.00
Yields & Fair Value
Earnings Yield-0.98%
Forward Earnings Yield2.92%
Dividend Yield0.00%
SharesGrow IV$7.81 (+203.9%)
Analyst Target$2.30 (-10.5%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -74.1 0.30 2.62 159.14 -
2017 -732.3 63.66 15.81 334.58 -
2018 -86.3 -0.12 12.02 154.03 -
2019 2.0 0.00 1.36 100.14 -
2020 -33.4 0.32 1.43 52.23 -
2021 -3.7 -0.01 1.09 22.49 -
2022 -5.7 0.10 0.84 11.04 -
2023 -11.4 0.20 0.77 9.66 -
2024 18.8 -0.12 0.73 6.56 -
2025 -107.3 0.88 0.93 5.24 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-0.01 $412.32K $-885K -214.6%
2017 $-0.01 $3.25M $-1.48M -45.7%
2018 $-0.08 $12.12M $-21.64M -178.5%
2019 $7.16 $23.75M $1.17B 4907.7%
2020 $-0.21 $46.72M $-74.62M -159.7%
2021 $-1.07 $74.44M $-396.7M -533%
2022 $-0.45 $91.9M $-168.73M -183.6%
2023 $-0.19 $87.24M $-73.96M -84.8%
2024 $0.11 $117.62M $41.08M 34.9%
2025 $-0.02 $193.36M $-9.45M -4.9%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $0.08 $0.07 – $0.08 $186.17M $185.98M – $186.35M 1
2027 $0.09 $0.04 – $0.14 $207.85M $206.37M – $209.32M 2
2028 $0.14 $0.14 – $0.14 $202.82M $201.38M – $204.26M 1
2029 $0.15 $0.15 – $0.15 $162.47M $161.31M – $163.62M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message